Drug
Amx0035
Amx0035: highest development phase Phase 3, developed by Amylyx Pharmaceuticals. 9 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Amylyx Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| AMX0035 NCT05021536 | Phase 3 | Amyotrophic Lateral Sclerosis |
| AMX0035 NCT05619783 | Phase 3 | Amyotrophic Lateral Sclerosis |
| AMX0035 NCT04516096 | Phase 2/3 | Amyotrophic Lateral Sclerosis |
| AMX0035 NCT06122662 | Phase 2/3 | Progressive Supranuclear Palsy |
| AMX0035 NCT05676034 | Phase 2 | Wolfram Syndrome |
| AMX0035 NCT03127514 | Phase 2 | Amyotrophic Lateral Sclerosis |
| AMX0035 NCT03533257 | Phase 2 | Alzheimer Disease |
| AMX0035 NCT03488524 | Phase 2 | Amyotrophic Lateral Sclerosis |
| AMX0035 NCT04987671 | Phase 1/2 | ALS |
Latest
No recent events.
Follow Amx0035 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.